#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=The energy applicator may be an electromagnetic (EM) energy applicator in which case the applicator can take many known forms, such as a coiled conductor in the catheter, or may be an ultrasonic energy applicator in which case the applicator may take the form of a stack of piezo-electric cylinders in the catheter.
1-1	0-3	The	_	_	
1-2	4-10	energy	_	_	
1-3	11-21	applicator	_	_	
1-4	22-25	may	_	_	
1-5	26-28	be	_	_	
1-6	29-31	an	_	_	
1-7	32-47	electromagnetic	_	_	
1-8	48-49	(	_	_	
1-9	49-51	EM	_	_	
1-10	51-52	)	_	_	
1-11	53-59	energy	_	_	
1-12	60-70	applicator	_	_	
1-13	71-73	in	_	_	
1-14	74-79	which	_	_	
1-15	80-84	case	_	_	
1-16	85-88	the	_	_	
1-17	89-99	applicator	_	_	
1-18	100-103	can	_	_	
1-19	104-108	take	_	_	
1-20	109-113	many	_	_	
1-21	114-119	known	_	_	
1-22	120-125	forms	_	_	
1-23	125-126	,	_	_	
1-24	127-131	such	_	_	
1-25	132-134	as	_	_	
1-26	135-136	a	_	_	
1-27	137-143	coiled	_	_	
1-28	144-153	conductor	_	_	
1-29	154-156	in	_	_	
1-30	157-160	the	_	_	
1-31	161-169	catheter	_	_	
1-32	169-170	,	_	_	
1-33	171-173	or	_	_	
1-34	174-177	may	_	_	
1-35	178-180	be	_	_	
1-36	181-183	an	_	_	
1-37	184-194	ultrasonic	_	_	
1-38	195-201	energy	_	_	
1-39	202-212	applicator	_	_	
1-40	213-215	in	_	_	
1-41	216-221	which	_	_	
1-42	222-226	case	_	_	
1-43	227-230	the	_	_	
1-44	231-241	applicator	_	_	
1-45	242-245	may	_	_	
1-46	246-250	take	_	_	
1-47	251-254	the	_	_	
1-48	255-259	form	_	_	
1-49	260-262	of	_	_	
1-50	263-264	a	_	_	
1-51	265-270	stack	_	_	
1-52	271-273	of	_	_	
1-53	274-288	piezo-electric	_	_	
1-54	289-298	cylinders	_	_	
1-55	299-301	in	_	_	
1-56	302-305	the	_	_	
1-57	306-314	catheter	_	_	
1-58	314-315	.	_	_	

#Text=The piezo-electric cylinders convert the EM energy into high frequency mechanical movement of the material.
2-1	316-319	The	_	_	
2-2	320-334	piezo-electric	_	_	
2-3	335-344	cylinders	_	_	
2-4	345-352	convert	_	_	
2-5	353-356	the	_	_	
2-6	357-359	EM	_	_	
2-7	360-366	energy	_	_	
2-8	367-371	into	_	_	
2-9	372-376	high	_	_	
2-10	377-386	frequency	_	_	
2-11	387-397	mechanical	_	_	
2-12	398-406	movement	_	_	
2-13	407-409	of	_	_	
2-14	410-413	the	_	_	
2-15	414-422	material	_	_	
2-16	422-423	.	_	_	

#Text=This high frequency mechanical movement causes ultrasound radiation to be sent into the tissues surrounding the applicator to cause heating of the tissue.
3-1	424-428	This	_	_	
3-2	429-433	high	_	_	
3-3	434-443	frequency	_	_	
3-4	444-454	mechanical	_	_	
3-5	455-463	movement	_	_	
3-6	464-470	causes	_	_	
3-7	471-481	ultrasound	_	_	
3-8	482-491	radiation	_	_	
3-9	492-494	to	_	_	
3-10	495-497	be	_	_	
3-11	498-502	sent	_	_	
3-12	503-507	into	_	_	
3-13	508-511	the	_	_	
3-14	512-519	tissues	_	_	
3-15	520-531	surrounding	_	_	
3-16	532-535	the	_	_	
3-17	536-546	applicator	_	_	
3-18	547-549	to	_	_	
3-19	550-555	cause	_	_	
3-20	556-563	heating	_	_	
3-21	564-566	of	_	_	
3-22	567-570	the	_	_	
3-23	571-577	tissue	_	_	
3-24	577-578	.	_	_	

#Text=The catheter preferably includes an applicator positioning means for positioning the applicator in the prostate gland adjacent the tissue to be heated and for maintaining the position during treatment.
4-1	579-582	The	_	_	
4-2	583-591	catheter	_	_	
4-3	592-602	preferably	_	_	
4-4	603-611	includes	_	_	
4-5	612-614	an	_	_	
4-6	615-625	applicator	_	_	
4-7	626-637	positioning	_	_	
4-8	638-643	means	_	_	
4-9	644-647	for	_	_	
4-10	648-659	positioning	_	_	
4-11	660-663	the	_	_	
4-12	664-674	applicator	_	_	
4-13	675-677	in	_	_	
4-14	678-681	the	_	_	
4-15	682-690	prostate	_	_	
4-16	691-696	gland	_	_	
4-17	697-705	adjacent	_	_	
4-18	706-709	the	_	_	
4-19	710-716	tissue	_	_	
4-20	717-719	to	_	_	
4-21	720-722	be	_	_	
4-22	723-729	heated	_	_	
4-23	730-733	and	_	_	
4-24	734-737	for	_	_	
4-25	738-749	maintaining	_	_	
4-26	750-753	the	_	_	
4-27	754-762	position	_	_	
4-28	763-769	during	_	_	
4-29	770-779	treatment	_	_	
4-30	779-780	.	_	_	

#Text=The applicator is suitably sheathed to provide an external substantially uniform tissue heating field to be radiated at nearly all transverse cross sections along the applicator for substantially uniform tissue heating.
5-1	781-784	The	_	_	
5-2	785-795	applicator	_	_	
5-3	796-798	is	_	_	
5-4	799-807	suitably	_	_	
5-5	808-816	sheathed	_	_	
5-6	817-819	to	_	_	
5-7	820-827	provide	_	_	
5-8	828-830	an	_	_	
5-9	831-839	external	_	_	
5-10	840-853	substantially	_	_	
5-11	854-861	uniform	_	_	
5-12	862-868	tissue	_	_	
5-13	869-876	heating	_	_	
5-14	877-882	field	_	_	
5-15	883-885	to	_	_	
5-16	886-888	be	_	_	
5-17	889-897	radiated	_	_	
5-18	898-900	at	_	_	
5-19	901-907	nearly	_	_	
5-20	908-911	all	_	_	
5-21	912-922	transverse	_	_	
5-22	923-928	cross	_	_	
5-23	929-937	sections	_	_	
5-24	938-943	along	_	_	
5-25	944-947	the	_	_	
5-26	948-958	applicator	_	_	
5-27	959-962	for	_	_	
5-28	963-976	substantially	_	_	
5-29	977-984	uniform	_	_	
5-30	985-991	tissue	_	_	
5-31	992-999	heating	_	_	
5-32	999-1000	.	_	_	

#Text=A principal feature distinguishing the present invention from the prior art devices is the provision of a urethral insertable EM or US radiation applicator, system, and method principally adapted for benign prostatic hyperplasia (BPH), which provides the generally cylindrical or longitudinally uniform EM or US radiation heating pattern necessary to enable substantially uniform heating of BPH growths or other tissue diseases associated with the urinary track, by the combined use of circulating cooling fluid inside the applicator and monitoring the heated prostatic tissue temperature by using microwave radiometry.
6-1	1001-1002	A	*[1]	8-1[2_1]	
6-2	1003-1012	principal	*[1]	_	
6-3	1013-1020	feature	*[1]	_	
6-4	1021-1035	distinguishing	*[1]	_	
6-5	1036-1039	the	*[1]	_	
6-6	1040-1047	present	*[1]	_	
6-7	1048-1057	invention	*[1]	_	
6-8	1058-1062	from	*[1]	_	
6-9	1063-1066	the	*[1]	_	
6-10	1067-1072	prior	*[1]	_	
6-11	1073-1076	art	*[1]	_	
6-12	1077-1084	devices	*[1]	_	
6-13	1085-1087	is	*[1]	_	
6-14	1088-1091	the	*[1]	_	
6-15	1092-1101	provision	*[1]	_	
6-16	1102-1104	of	*[1]	_	
6-17	1105-1106	a	*[1]	_	
6-18	1107-1115	urethral	*[1]	_	
6-19	1116-1126	insertable	*[1]	_	
6-20	1127-1129	EM	*[1]	_	
6-21	1130-1132	or	*[1]	_	
6-22	1133-1135	US	*[1]	_	
6-23	1136-1145	radiation	*[1]	_	
6-24	1146-1156	applicator	*[1]	_	
6-25	1156-1157	,	*[1]	_	
6-26	1158-1164	system	*[1]	_	
6-27	1164-1165	,	*[1]	_	
6-28	1166-1169	and	*[1]	_	
6-29	1170-1176	method	*[1]	_	
6-30	1177-1188	principally	*[1]	_	
6-31	1189-1196	adapted	*[1]	_	
6-32	1197-1200	for	*[1]	_	
6-33	1201-1207	benign	*[1]	_	
6-34	1208-1217	prostatic	*[1]	_	
6-35	1218-1229	hyperplasia	*[1]	_	
6-36	1230-1231	(	*[1]	_	
6-37	1231-1234	BPH	*[1]	_	
6-38	1234-1235	)	*[1]	_	
6-39	1235-1236	,	*[1]	_	
6-40	1237-1242	which	*[1]	_	
6-41	1243-1251	provides	*[1]	_	
6-42	1252-1255	the	*[1]	_	
6-43	1256-1265	generally	*[1]	_	
6-44	1266-1277	cylindrical	*[1]	_	
6-45	1278-1280	or	*[1]	_	
6-46	1281-1295	longitudinally	*[1]	_	
6-47	1296-1303	uniform	*[1]	_	
6-48	1304-1306	EM	*[1]	_	
6-49	1307-1309	or	*[1]	_	
6-50	1310-1312	US	*[1]	_	
6-51	1313-1322	radiation	*[1]	_	
6-52	1323-1330	heating	*[1]	_	
6-53	1331-1338	pattern	*[1]	_	
6-54	1339-1348	necessary	*[1]	_	
6-55	1349-1351	to	*[1]	_	
6-56	1352-1358	enable	*[1]	_	
6-57	1359-1372	substantially	*[1]	_	
6-58	1373-1380	uniform	*[1]	_	
6-59	1381-1388	heating	*[1]	_	
6-60	1389-1391	of	*[1]	_	
6-61	1392-1395	BPH	*[1]	_	
6-62	1396-1403	growths	*[1]	_	
6-63	1404-1406	or	*[1]	_	
6-64	1407-1412	other	*[1]	_	
6-65	1413-1419	tissue	*[1]	_	
6-66	1420-1428	diseases	*[1]	_	
6-67	1429-1439	associated	*[1]	_	
6-68	1440-1444	with	*[1]	_	
6-69	1445-1448	the	*[1]	_	
6-70	1449-1456	urinary	*[1]	_	
6-71	1457-1462	track	*[1]	_	
6-72	1462-1463	,	*[1]	_	
6-73	1464-1466	by	*[1]	_	
6-74	1467-1470	the	*[1]	_	
6-75	1471-1479	combined	*[1]	_	
6-76	1480-1483	use	*[1]	_	
6-77	1484-1486	of	*[1]	_	
6-78	1487-1498	circulating	*[1]	_	
6-79	1499-1506	cooling	*[1]	_	
6-80	1507-1512	fluid	*[1]	_	
6-81	1513-1519	inside	*[1]	_	
6-82	1520-1523	the	*[1]	_	
6-83	1524-1534	applicator	*[1]	_	
6-84	1535-1538	and	*[1]	_	
6-85	1539-1549	monitoring	*[1]	_	
6-86	1550-1553	the	*[1]	_	
6-87	1554-1560	heated	*[1]	_	
6-88	1561-1570	prostatic	*[1]	_	
6-89	1571-1577	tissue	*[1]	_	
6-90	1578-1589	temperature	*[1]	_	
6-91	1590-1592	by	*[1]	_	
6-92	1593-1598	using	*[1]	_	
6-93	1599-1608	microwave	*[1]	_	
6-94	1609-1619	radiometry	*[1]	_	
6-95	1619-1620	.	*[1]	_	

#Text=The unique use of microwave or US radiation radiometry with cooling in a microwave or US radiation applicator for the treatment of the prostate has a specific therapeutic advantage not obtained by other methods and systems.
7-1	1621-1624	The	_	_	
7-2	1625-1631	unique	_	_	
7-3	1632-1635	use	_	_	
7-4	1636-1638	of	_	_	
7-5	1639-1648	microwave	_	_	
7-6	1649-1651	or	_	_	
7-7	1652-1654	US	_	_	
7-8	1655-1664	radiation	_	_	
7-9	1665-1675	radiometry	_	_	
7-10	1676-1680	with	_	_	
7-11	1681-1688	cooling	_	_	
7-12	1689-1691	in	_	_	
7-13	1692-1693	a	_	_	
7-14	1694-1703	microwave	_	_	
7-15	1704-1706	or	_	_	
7-16	1707-1709	US	_	_	
7-17	1710-1719	radiation	_	_	
7-18	1720-1730	applicator	_	_	
7-19	1731-1734	for	_	_	
7-20	1735-1738	the	_	_	
7-21	1739-1748	treatment	_	_	
7-22	1749-1751	of	_	_	
7-23	1752-1755	the	_	_	
7-24	1756-1764	prostate	_	_	
7-25	1765-1768	has	_	_	
7-26	1769-1770	a	_	_	
7-27	1771-1779	specific	_	_	
7-28	1780-1791	therapeutic	_	_	
7-29	1792-1801	advantage	_	_	
7-30	1802-1805	not	_	_	
7-31	1806-1814	obtained	_	_	
7-32	1815-1817	by	_	_	
7-33	1818-1823	other	_	_	
7-34	1824-1831	methods	_	_	
7-35	1832-1835	and	_	_	
7-36	1836-1843	systems	_	_	
7-37	1843-1844	.	_	_	

#Text=This method is capable of greatly improving the therapeutic effect from even one treatment.
8-1	1845-1849	This	*[2]	_	
8-2	1850-1856	method	*[2]	_	
8-3	1857-1859	is	_	_	
8-4	1860-1867	capable	_	_	
8-5	1868-1870	of	_	_	
8-6	1871-1878	greatly	_	_	
8-7	1879-1888	improving	_	_	
8-8	1889-1892	the	_	_	
8-9	1893-1904	therapeutic	_	_	
8-10	1905-1911	effect	_	_	
8-11	1912-1916	from	_	_	
8-12	1917-1921	even	_	_	
8-13	1922-1925	one	_	_	
8-14	1926-1935	treatment	_	_	
8-15	1935-1936	.	_	_	

#Text=The hyperthermia treatments with other systems which use an applicator inserted into the urethra do not contain fluid circulation cooling and microwave or US radiation radiometric temperature measurements.
9-1	1937-1940	The	_	_	
9-2	1941-1953	hyperthermia	_	_	
9-3	1954-1964	treatments	_	_	
9-4	1965-1969	with	_	_	
9-5	1970-1975	other	_	_	
9-6	1976-1983	systems	_	_	
9-7	1984-1989	which	_	_	
9-8	1990-1993	use	_	_	
9-9	1994-1996	an	_	_	
9-10	1997-2007	applicator	_	_	
9-11	2008-2016	inserted	_	_	
9-12	2017-2021	into	_	_	
9-13	2022-2025	the	_	_	
9-14	2026-2033	urethra	_	_	
9-15	2034-2036	do	_	_	
9-16	2037-2040	not	_	_	
9-17	2041-2048	contain	_	_	
9-18	2049-2054	fluid	_	_	
9-19	2055-2066	circulation	_	_	
9-20	2067-2074	cooling	_	_	
9-21	2075-2078	and	_	_	
9-22	2079-2088	microwave	_	_	
9-23	2089-2091	or	_	_	
9-24	2092-2094	US	_	_	
9-25	2095-2104	radiation	_	_	
9-26	2105-2116	radiometric	_	_	
9-27	2117-2128	temperature	_	_	
9-28	2129-2141	measurements	_	_	
9-29	2141-2142	.	_	_	

#Text=The unique combination of these methods enable therapeutic heating of a much larger prostate tissue volume than other methods as well as a reliable and accurate measurement of the therapeutic temperature of the heated prostate tissues.
10-1	2143-2146	The	_	_	
10-2	2147-2153	unique	_	_	
10-3	2154-2165	combination	_	_	
10-4	2166-2168	of	_	_	
10-5	2169-2174	these	_	_	
10-6	2175-2182	methods	_	_	
10-7	2183-2189	enable	_	_	
10-8	2190-2201	therapeutic	_	_	
10-9	2202-2209	heating	_	_	
10-10	2210-2212	of	_	_	
10-11	2213-2214	a	_	_	
10-12	2215-2219	much	_	_	
10-13	2220-2226	larger	_	_	
10-14	2227-2235	prostate	_	_	
10-15	2236-2242	tissue	_	_	
10-16	2243-2249	volume	_	_	
10-17	2250-2254	than	_	_	
10-18	2255-2260	other	_	_	
10-19	2261-2268	methods	_	_	
10-20	2269-2271	as	_	_	
10-21	2272-2276	well	_	_	
10-22	2277-2279	as	_	_	
10-23	2280-2281	a	_	_	
10-24	2282-2290	reliable	_	_	
10-25	2291-2294	and	_	_	
10-26	2295-2303	accurate	_	_	
10-27	2304-2315	measurement	_	_	
10-28	2316-2318	of	_	_	
10-29	2319-2322	the	_	_	
10-30	2323-2334	therapeutic	_	_	
10-31	2335-2346	temperature	_	_	
10-32	2347-2349	of	_	_	
10-33	2350-2353	the	_	_	
10-34	2354-2360	heated	_	_	
10-35	2361-2369	prostate	_	_	
10-36	2370-2377	tissues	_	_	
10-37	2377-2378	.	_	_	

#Text=It has been observed in treatments not using cooling in the urethra inserted applicators, that the therapeutic temperatures are limited to about a 6 mm radial depth from the inserted applicator wall.
11-1	2379-2381	It	_	_	
11-2	2382-2385	has	_	_	
11-3	2386-2390	been	_	_	
11-4	2391-2399	observed	_	_	
11-5	2400-2402	in	_	_	
11-6	2403-2413	treatments	_	_	
11-7	2414-2417	not	_	_	
11-8	2418-2423	using	_	_	
11-9	2424-2431	cooling	_	_	
11-10	2432-2434	in	_	_	
11-11	2435-2438	the	_	_	
11-12	2439-2446	urethra	_	_	
11-13	2447-2455	inserted	_	_	
11-14	2456-2467	applicators	_	_	
11-15	2467-2468	,	_	_	
11-16	2469-2473	that	_	_	
11-17	2474-2477	the	_	_	
11-18	2478-2489	therapeutic	_	_	
11-19	2490-2502	temperatures	_	_	
11-20	2503-2506	are	_	_	
11-21	2507-2514	limited	_	_	
11-22	2515-2517	to	_	_	
11-23	2518-2523	about	_	_	
11-24	2524-2525	a	_	_	
11-25	2526-2527	6	_	_	
11-26	2528-2530	mm	_	_	
11-27	2531-2537	radial	_	_	
11-28	2538-2543	depth	_	_	
11-29	2544-2548	from	_	_	
11-30	2549-2552	the	_	_	
11-31	2553-2561	inserted	_	_	
11-32	2562-2572	applicator	_	_	
11-33	2573-2577	wall	_	_	
11-34	2577-2578	.	_	_	

#Text=As previously indicated, the tissue layer causing patient problems is usually less than 10 mm in depth, however, in many cases it will be greater than 6 mm, therefore, the therapeutic temperatures may not extend completely through the tissue layer to be heated.
12-1	2579-2581	As	_	_	
12-2	2582-2592	previously	_	_	
12-3	2593-2602	indicated	_	_	
12-4	2602-2603	,	_	_	
12-5	2604-2607	the	_	_	
12-6	2608-2614	tissue	_	_	
12-7	2615-2620	layer	_	_	
12-8	2621-2628	causing	_	_	
12-9	2629-2636	patient	_	_	
12-10	2637-2645	problems	_	_	
12-11	2646-2648	is	_	_	
12-12	2649-2656	usually	_	_	
12-13	2657-2661	less	_	_	
12-14	2662-2666	than	_	_	
12-15	2667-2669	10	_	_	
12-16	2670-2672	mm	_	_	
12-17	2673-2675	in	_	_	
12-18	2676-2681	depth	_	_	
12-19	2681-2682	,	_	_	
12-20	2683-2690	however	_	_	
12-21	2690-2691	,	_	_	
12-22	2692-2694	in	_	_	
12-23	2695-2699	many	_	_	
12-24	2700-2705	cases	_	_	
12-25	2706-2708	it	_	_	
12-26	2709-2713	will	_	_	
12-27	2714-2716	be	_	_	
12-28	2717-2724	greater	_	_	
12-29	2725-2729	than	_	_	
12-30	2730-2731	6	_	_	
12-31	2732-2734	mm	_	_	
12-32	2734-2735	,	_	_	
12-33	2736-2745	therefore	_	_	
12-34	2745-2746	,	_	_	
12-35	2747-2750	the	_	_	
12-36	2751-2762	therapeutic	_	_	
12-37	2763-2775	temperatures	_	_	
12-38	2776-2779	may	_	_	
12-39	2780-2783	not	_	_	
12-40	2784-2790	extend	_	_	
12-41	2791-2801	completely	_	_	
12-42	2802-2809	through	_	_	
12-43	2810-2813	the	_	_	
12-44	2814-2820	tissue	_	_	
12-45	2821-2826	layer	_	_	
12-46	2827-2829	to	_	_	
12-47	2830-2832	be	_	_	
12-48	2833-2839	heated	_	_	
12-49	2839-2840	.	_	_	

#Text=In addition, there appears to be the need for between five and ten one hour treatments at temperatures ranging between 43.degree. to 50.degree.
13-1	2841-2843	In	_	_	
13-2	2844-2852	addition	_	_	
13-3	2852-2853	,	_	_	
13-4	2854-2859	there	_	_	
13-5	2860-2867	appears	_	_	
13-6	2868-2870	to	_	_	
13-7	2871-2873	be	_	_	
13-8	2874-2877	the	_	_	
13-9	2878-2882	need	_	_	
13-10	2883-2886	for	_	_	
13-11	2887-2894	between	_	_	
13-12	2895-2899	five	_	_	
13-13	2900-2903	and	_	_	
13-14	2904-2907	ten	_	_	
13-15	2908-2911	one	_	_	
13-16	2912-2916	hour	_	_	
13-17	2917-2927	treatments	_	_	
13-18	2928-2930	at	_	_	
13-19	2931-2943	temperatures	_	_	
13-20	2944-2951	ranging	_	_	
13-21	2952-2959	between	_	_	
13-22	2960-2962	43	_	_	
13-23	2962-2963	.	_	_	
13-24	2963-2969	degree	_	_	
13-25	2969-2970	.	_	_	
13-26	2971-2973	to	_	_	
13-27	2974-2976	50	_	_	
13-28	2976-2977	.	_	_	
13-29	2977-2983	degree	_	_	
13-30	2983-2984	.	_	_	

#Text=C.
14-1	2985-2986	C	_	_	
14-2	2986-2987	.	_	_	

#Text=These treatments are delivered once or twice a week.
15-1	2988-2993	These	_	_	
15-2	2994-3004	treatments	_	_	
15-3	3005-3008	are	_	_	
15-4	3009-3018	delivered	_	_	
15-5	3019-3023	once	_	_	
15-6	3024-3026	or	_	_	
15-7	3027-3032	twice	_	_	
15-8	3033-3034	a	_	_	
15-9	3035-3039	week	_	_	
15-10	3039-3040	.	_	_	

#Text=Early results indicate that there is a greater therapeutic benefit by the delivery of ten treatments as compared to five.
16-1	3041-3046	Early	_	_	
16-2	3047-3054	results	_	_	
16-3	3055-3063	indicate	_	_	
16-4	3064-3068	that	_	_	
16-5	3069-3074	there	_	_	
16-6	3075-3077	is	_	_	
16-7	3078-3079	a	_	_	
16-8	3080-3087	greater	_	_	
16-9	3088-3099	therapeutic	_	_	
16-10	3100-3107	benefit	_	_	
16-11	3108-3110	by	_	_	
16-12	3111-3114	the	_	_	
16-13	3115-3123	delivery	_	_	
16-14	3124-3126	of	_	_	
16-15	3127-3130	ten	_	_	
16-16	3131-3141	treatments	_	_	
16-17	3142-3144	as	_	_	
16-18	3145-3153	compared	_	_	
16-19	3154-3156	to	_	_	
16-20	3157-3161	five	_	_	
16-21	3161-3162	.	_	_	

#Text=The present methods, which are without prostate urethra cooling and microwave radiometry for temperature measurement, cause the greatest tissue temperatures along the applicator/tissue interface.
17-1	3163-3166	The	_	_	
17-2	3167-3174	present	_	_	
17-3	3175-3182	methods	_	_	
17-4	3182-3183	,	_	_	
17-5	3184-3189	which	_	_	
17-6	3190-3193	are	_	_	
17-7	3194-3201	without	_	_	
17-8	3202-3210	prostate	_	_	
17-9	3211-3218	urethra	_	_	
17-10	3219-3226	cooling	_	_	
17-11	3227-3230	and	_	_	
17-12	3231-3240	microwave	_	_	
17-13	3241-3251	radiometry	_	_	
17-14	3252-3255	for	_	_	
17-15	3256-3267	temperature	_	_	
17-16	3268-3279	measurement	_	_	
17-17	3279-3280	,	_	_	
17-18	3281-3286	cause	_	_	
17-19	3287-3290	the	_	_	
17-20	3291-3299	greatest	_	_	
17-21	3300-3306	tissue	_	_	
17-22	3307-3319	temperatures	_	_	
17-23	3320-3325	along	_	_	
17-24	3326-3329	the	_	_	
17-25	3330-3340	applicator	_	_	
17-26	3340-3341	/	_	_	
17-27	3341-3347	tissue	_	_	
17-28	3348-3357	interface	_	_	
17-29	3357-3358	.	_	_	

#Text=This is because the microwave power is more intense nearest the applicator radiator.
18-1	3359-3363	This	_	_	
18-2	3364-3366	is	_	_	
18-3	3367-3374	because	_	_	
18-4	3375-3378	the	_	_	
18-5	3379-3388	microwave	_	_	
18-6	3389-3394	power	_	_	
18-7	3395-3397	is	_	_	
18-8	3398-3402	more	_	_	
18-9	3403-3410	intense	_	_	
18-10	3411-3418	nearest	_	_	
18-11	3419-3422	the	_	_	
18-12	3423-3433	applicator	_	_	
18-13	3434-3442	radiator	_	_	
18-14	3442-3443	.	_	_	

#Text=This mechanism enables a temperature sensor to be attached to the applicator wall to at least measure the prostate tissue temperatures along the wall.
19-1	3444-3448	This	_	_	
19-2	3449-3458	mechanism	_	_	
19-3	3459-3466	enables	_	_	
19-4	3467-3468	a	_	_	
19-5	3469-3480	temperature	_	_	
19-6	3481-3487	sensor	_	_	
19-7	3488-3490	to	_	_	
19-8	3491-3493	be	_	_	
19-9	3494-3502	attached	_	_	
19-10	3503-3505	to	_	_	
19-11	3506-3509	the	_	_	
19-12	3510-3520	applicator	_	_	
19-13	3521-3525	wall	_	_	
19-14	3526-3528	to	_	_	
19-15	3529-3531	at	_	_	
19-16	3532-3537	least	_	_	
19-17	3538-3545	measure	_	_	
19-18	3546-3549	the	_	_	
19-19	3550-3558	prostate	_	_	
19-20	3559-3565	tissue	_	_	
19-21	3566-3578	temperatures	_	_	
19-22	3579-3584	along	_	_	
19-23	3585-3588	the	_	_	
19-24	3589-3593	wall	_	_	
19-25	3593-3594	.	_	_	

#Text=When the cooling is added along the applicator wall, the excessive tissue temperatures are reduced.
20-1	3595-3599	When	_	_	
20-2	3600-3603	the	_	_	
20-3	3604-3611	cooling	_	_	
20-4	3612-3614	is	_	_	
20-5	3615-3620	added	_	_	
20-6	3621-3626	along	_	_	
20-7	3627-3630	the	_	_	
20-8	3631-3641	applicator	_	_	
20-9	3642-3646	wall	_	_	
20-10	3646-3647	,	_	_	
20-11	3648-3651	the	_	_	
20-12	3652-3661	excessive	_	_	
20-13	3662-3668	tissue	_	_	
20-14	3669-3681	temperatures	_	_	
20-15	3682-3685	are	_	_	
20-16	3686-3693	reduced	_	_	
20-17	3693-3694	.	_	_	

#Text=This enables more power to be introduced to heat a greater volume of tissue to therapeutic levels.
21-1	3695-3699	This	_	_	
21-2	3700-3707	enables	_	_	
21-3	3708-3712	more	_	_	
21-4	3713-3718	power	_	_	
21-5	3719-3721	to	_	_	
21-6	3722-3724	be	_	_	
21-7	3725-3735	introduced	_	_	
21-8	3736-3738	to	_	_	
21-9	3739-3743	heat	_	_	
21-10	3744-3745	a	_	_	
21-11	3746-3753	greater	_	_	
21-12	3754-3760	volume	_	_	
21-13	3761-3763	of	_	_	
21-14	3764-3770	tissue	_	_	
21-15	3771-3773	to	_	_	
21-16	3774-3785	therapeutic	_	_	
21-17	3786-3792	levels	_	_	
21-18	3792-3793	.	_	_	

#Text=Because a larger volume of tissue is heated to a therapeutic level in each treatment, the need for repeated treatments is decreased.
22-1	3794-3801	Because	_	_	
22-2	3802-3803	a	_	_	
22-3	3804-3810	larger	_	_	
22-4	3811-3817	volume	_	_	
22-5	3818-3820	of	_	_	
22-6	3821-3827	tissue	_	_	
22-7	3828-3830	is	_	_	
22-8	3831-3837	heated	_	_	
22-9	3838-3840	to	_	_	
22-10	3841-3842	a	_	_	
22-11	3843-3854	therapeutic	_	_	
22-12	3855-3860	level	_	_	
22-13	3861-3863	in	_	_	
22-14	3864-3868	each	_	_	
22-15	3869-3878	treatment	_	_	
22-16	3878-3879	,	_	_	
22-17	3880-3883	the	_	_	
22-18	3884-3888	need	_	_	
22-19	3889-3892	for	_	_	
22-20	3893-3901	repeated	_	_	
22-21	3902-3912	treatments	_	_	
22-22	3913-3915	is	_	_	
22-23	3916-3925	decreased	_	_	
22-24	3925-3926	.	_	_	

#Text=It has been shown in cancer hyperthermia, that when the target tissues have been adequately treated even one or two times, they will completely respond.
23-1	3927-3929	It	_	_	
23-2	3930-3933	has	_	_	
23-3	3934-3938	been	_	_	
23-4	3939-3944	shown	_	_	
23-5	3945-3947	in	_	_	
23-6	3948-3954	cancer	_	_	
23-7	3955-3967	hyperthermia	_	_	
23-8	3967-3968	,	_	_	
23-9	3969-3973	that	_	_	
23-10	3974-3978	when	_	_	
23-11	3979-3982	the	_	_	
23-12	3983-3989	target	_	_	
23-13	3990-3997	tissues	_	_	
23-14	3998-4002	have	_	_	
23-15	4003-4007	been	_	_	
23-16	4008-4018	adequately	_	_	
23-17	4019-4026	treated	_	_	
23-18	4027-4031	even	_	_	
23-19	4032-4035	one	_	_	
23-20	4036-4038	or	_	_	
23-21	4039-4042	two	_	_	
23-22	4043-4048	times	_	_	
23-23	4048-4049	,	_	_	
23-24	4050-4054	they	_	_	
23-25	4055-4059	will	_	_	
23-26	4060-4070	completely	_	_	
23-27	4071-4078	respond	_	_	
23-28	4078-4079	.	_	_	

#Text=The response is normally measured by tissue necrosis.
24-1	4080-4083	The	_	_	
24-2	4084-4092	response	_	_	
24-3	4093-4095	is	_	_	
24-4	4096-4104	normally	_	_	
24-5	4105-4113	measured	_	_	
24-6	4114-4116	by	_	_	
24-7	4117-4123	tissue	_	_	
24-8	4124-4132	necrosis	_	_	
24-9	4132-4133	.	_	_	

#Text=These necrotic or dead tissues are normally absorbed and digested by the natural body process of removing dead cells.
25-1	4134-4139	These	_	_	
25-2	4140-4148	necrotic	_	_	
25-3	4149-4151	or	_	_	
25-4	4152-4156	dead	_	_	
25-5	4157-4164	tissues	_	_	
25-6	4165-4168	are	_	_	
25-7	4169-4177	normally	_	_	
25-8	4178-4186	absorbed	_	_	
25-9	4187-4190	and	_	_	
25-10	4191-4199	digested	_	_	
25-11	4200-4202	by	_	_	
25-12	4203-4206	the	_	_	
25-13	4207-4214	natural	_	_	
25-14	4215-4219	body	_	_	
25-15	4220-4227	process	_	_	
25-16	4228-4230	of	_	_	
25-17	4231-4239	removing	_	_	
25-18	4240-4244	dead	_	_	
25-19	4245-4250	cells	_	_	
25-20	4250-4251	.	_	_	

#Text=Thus, adequate treatment of the tissues within the prostate by even one good heat treatment of the entire target mass is expected to result in the full effect of therapy.
26-1	4252-4256	Thus	_	_	
26-2	4256-4257	,	_	_	
26-3	4258-4266	adequate	_	_	
26-4	4267-4276	treatment	_	_	
26-5	4277-4279	of	_	_	
26-6	4280-4283	the	_	_	
26-7	4284-4291	tissues	_	_	
26-8	4292-4298	within	_	_	
26-9	4299-4302	the	_	_	
26-10	4303-4311	prostate	_	_	
26-11	4312-4314	by	_	_	
26-12	4315-4319	even	_	_	
26-13	4320-4323	one	_	_	
26-14	4324-4328	good	_	_	
26-15	4329-4333	heat	_	_	
26-16	4334-4343	treatment	_	_	
26-17	4344-4346	of	_	_	
26-18	4347-4350	the	_	_	
26-19	4351-4357	entire	_	_	
26-20	4358-4364	target	_	_	
26-21	4365-4369	mass	_	_	
26-22	4370-4372	is	_	_	
26-23	4373-4381	expected	_	_	
26-24	4382-4384	to	_	_	
26-25	4385-4391	result	_	_	
26-26	4392-4394	in	_	_	
26-27	4395-4398	the	_	_	
26-28	4399-4403	full	_	_	
26-29	4404-4410	effect	_	_	
26-30	4411-4413	of	_	_	
26-31	4414-4421	therapy	_	_	
26-32	4421-4422	.	_	_	

#Text=This could reduce the number of required treatments from about ten to only one or two.
27-1	4423-4427	This	_	_	
27-2	4428-4433	could	_	_	
27-3	4434-4440	reduce	_	_	
27-4	4441-4444	the	_	_	
27-5	4445-4451	number	_	_	
27-6	4452-4454	of	_	_	
27-7	4455-4463	required	_	_	
27-8	4464-4474	treatments	_	_	
27-9	4475-4479	from	_	_	
27-10	4480-4485	about	_	_	
27-11	4486-4489	ten	_	_	
27-12	4490-4492	to	_	_	
27-13	4493-4497	only	_	_	
27-14	4498-4501	one	_	_	
27-15	4502-4504	or	_	_	
27-16	4505-4508	two	_	_	
27-17	4508-4509	.	_	_	

#Text=This could greatly reduce treatment costs and inconvenience.
28-1	4510-4514	This	_	_	
28-2	4515-4520	could	_	_	
28-3	4521-4528	greatly	_	_	
28-4	4529-4535	reduce	_	_	
28-5	4536-4545	treatment	_	_	
28-6	4546-4551	costs	_	_	
28-7	4552-4555	and	_	_	
28-8	4556-4569	inconvenience	_	_	
28-9	4569-4570	.	_	_	

#Text=The current methods using microwave urethra heating without cooling have been found to treat to a depth of about 0.6 cm and a length of about 4.5 cm.
29-1	4571-4574	The	_	_	
29-2	4575-4582	current	_	_	
29-3	4583-4590	methods	_	_	
29-4	4591-4596	using	_	_	
29-5	4597-4606	microwave	_	_	
29-6	4607-4614	urethra	_	_	
29-7	4615-4622	heating	_	_	
29-8	4623-4630	without	_	_	
29-9	4631-4638	cooling	_	_	
29-10	4639-4643	have	_	_	
29-11	4644-4648	been	_	_	
29-12	4649-4654	found	_	_	
29-13	4655-4657	to	_	_	
29-14	4658-4663	treat	_	_	
29-15	4664-4666	to	_	_	
29-16	4667-4668	a	_	_	
29-17	4669-4674	depth	_	_	
29-18	4675-4677	of	_	_	
29-19	4678-4683	about	_	_	
29-20	4684-4687	0.6	_	_	
29-21	4688-4690	cm	_	_	
29-22	4691-4694	and	_	_	
29-23	4695-4696	a	_	_	
29-24	4697-4703	length	_	_	
29-25	4704-4706	of	_	_	
29-26	4707-4712	about	_	_	
29-27	4713-4716	4.5	_	_	
29-28	4717-4719	cm	_	_	
29-29	4719-4720	.	_	_	

#Text=This results in a treated volume of about 9 cm.sup.3 for a mass of 9 grams.
30-1	4721-4725	This	_	_	
30-2	4726-4733	results	_	_	
30-3	4734-4736	in	_	_	
30-4	4737-4738	a	_	_	
30-5	4739-4746	treated	_	_	
30-6	4747-4753	volume	_	_	
30-7	4754-4756	of	_	_	
30-8	4757-4762	about	_	_	
30-9	4763-4764	9	_	_	
30-10	4765-4771	cm.sup	_	_	
30-11	4771-4773	.3	_	_	
30-12	4774-4777	for	_	_	
30-13	4778-4779	a	_	_	
30-14	4780-4784	mass	_	_	
30-15	4785-4787	of	_	_	
30-16	4788-4789	9	_	_	
30-17	4790-4795	grams	_	_	
30-18	4795-4796	.	_	_	

#Text=The most common surgical procedure to correct this urinary blockage or retention and other symptoms of benign prostate diseases is the trans-urethral resection of the prostate (TURP).
31-1	4797-4800	The	_	_	
31-2	4801-4805	most	_	_	
31-3	4806-4812	common	_	_	
31-4	4813-4821	surgical	_	_	
31-5	4822-4831	procedure	_	_	
31-6	4832-4834	to	_	_	
31-7	4835-4842	correct	_	_	
31-8	4843-4847	this	_	_	
31-9	4848-4855	urinary	_	_	
31-10	4856-4864	blockage	_	_	
31-11	4865-4867	or	_	_	
31-12	4868-4877	retention	_	_	
31-13	4878-4881	and	_	_	
31-14	4882-4887	other	_	_	
31-15	4888-4896	symptoms	_	_	
31-16	4897-4899	of	_	_	
31-17	4900-4906	benign	_	_	
31-18	4907-4915	prostate	_	_	
31-19	4916-4924	diseases	_	_	
31-20	4925-4927	is	_	_	
31-21	4928-4931	the	_	_	
31-22	4932-4946	trans-urethral	_	_	
31-23	4947-4956	resection	_	_	
31-24	4957-4959	of	_	_	
31-25	4960-4963	the	_	_	
31-26	4964-4972	prostate	_	_	
31-27	4973-4974	(	_	_	
31-28	4974-4978	TURP	_	_	
31-29	4978-4979	)	_	_	
31-30	4979-4980	.	_	_	

#Text=The TURP procedure normally involves the surgical removal of about 15 to 20 grams of prostate tissue along the urethra passage inside the length of the prostate gland.
32-1	4981-4984	The	_	_	
32-2	4985-4989	TURP	_	_	
32-3	4990-4999	procedure	_	_	
32-4	5000-5008	normally	_	_	
32-5	5009-5017	involves	_	_	
32-6	5018-5021	the	_	_	
32-7	5022-5030	surgical	_	_	
32-8	5031-5038	removal	_	_	
32-9	5039-5041	of	_	_	
32-10	5042-5047	about	_	_	
32-11	5048-5050	15	_	_	
32-12	5051-5053	to	_	_	
32-13	5054-5056	20	_	_	
32-14	5057-5062	grams	_	_	
32-15	5063-5065	of	_	_	
32-16	5066-5074	prostate	_	_	
32-17	5075-5081	tissue	_	_	
32-18	5082-5087	along	_	_	
32-19	5088-5091	the	_	_	
32-20	5092-5099	urethra	_	_	
32-21	5100-5107	passage	_	_	
32-22	5108-5114	inside	_	_	
32-23	5115-5118	the	_	_	
32-24	5119-5125	length	_	_	
32-25	5126-5128	of	_	_	
32-26	5129-5132	the	_	_	
32-27	5133-5141	prostate	_	_	
32-28	5142-5147	gland	_	_	
32-29	5147-5148	.	_	_	

#Text=Thus, less tissue is treated by the heat treatment in the first session, than is surgically removed to resolve the symptoms.
33-1	5149-5153	Thus	_	_	
33-2	5153-5154	,	_	_	
33-3	5155-5159	less	_	_	
33-4	5160-5166	tissue	_	_	
33-5	5167-5169	is	_	_	
33-6	5170-5177	treated	_	_	
33-7	5178-5180	by	_	_	
33-8	5181-5184	the	_	_	
33-9	5185-5189	heat	_	_	
33-10	5190-5199	treatment	_	_	
33-11	5200-5202	in	_	_	
33-12	5203-5206	the	_	_	
33-13	5207-5212	first	_	_	
33-14	5213-5220	session	_	_	
33-15	5220-5221	,	_	_	
33-16	5222-5226	than	_	_	
33-17	5227-5229	is	_	_	
33-18	5230-5240	surgically	_	_	
33-19	5241-5248	removed	_	_	
33-20	5249-5251	to	_	_	
33-21	5252-5259	resolve	_	_	
33-22	5260-5263	the	_	_	
33-23	5264-5272	symptoms	_	_	
33-24	5272-5273	.	_	_	

#Text=After the first treatment with current methods, some of the prostate tissues become necrotic and begin to recede by the body's removal of the dead cells.
34-1	5274-5279	After	_	_	
34-2	5280-5283	the	_	_	
34-3	5284-5289	first	_	_	
34-4	5290-5299	treatment	_	_	
34-5	5300-5304	with	_	_	
34-6	5305-5312	current	_	_	
34-7	5313-5320	methods	_	_	
34-8	5320-5321	,	_	_	
34-9	5322-5326	some	_	_	
34-10	5327-5329	of	_	_	
34-11	5330-5333	the	_	_	
34-12	5334-5342	prostate	_	_	
34-13	5343-5350	tissues	_	_	
34-14	5351-5357	become	_	_	
34-15	5358-5366	necrotic	_	_	
34-16	5367-5370	and	_	_	
34-17	5371-5376	begin	_	_	
34-18	5377-5379	to	_	_	
34-19	5380-5386	recede	_	_	
34-20	5387-5389	by	_	_	
34-21	5390-5393	the	_	_	
34-22	5394-5400	body's	_	_	
34-23	5401-5408	removal	_	_	
34-24	5409-5411	of	_	_	
34-25	5412-5415	the	_	_	
34-26	5416-5420	dead	_	_	
34-27	5421-5426	cells	_	_	
34-28	5426-5427	.	_	_	

#Text=By the next heat treatment several days later, some of the original tissue is most likely not present.
35-1	5428-5430	By	_	_	
35-2	5431-5434	the	_	_	
35-3	5435-5439	next	_	_	
35-4	5440-5444	heat	_	_	
35-5	5445-5454	treatment	_	_	
35-6	5455-5462	several	_	_	
35-7	5463-5467	days	_	_	
35-8	5468-5473	later	_	_	
35-9	5473-5474	,	_	_	
35-10	5475-5479	some	_	_	
35-11	5480-5482	of	_	_	
35-12	5483-5486	the	_	_	
35-13	5487-5495	original	_	_	
35-14	5496-5502	tissue	_	_	
35-15	5503-5505	is	_	_	
35-16	5506-5510	most	_	_	
35-17	5511-5517	likely	_	_	
35-18	5518-5521	not	_	_	
35-19	5522-5529	present	_	_	
35-20	5529-5530	.	_	_	

#Text=This enables a second heat treatment to adequately heat tissues which were beyond the heating depth of the first treatment.
36-1	5531-5535	This	_	_	
36-2	5536-5543	enables	_	_	
36-3	5544-5545	a	_	_	
36-4	5546-5552	second	_	_	
36-5	5553-5557	heat	_	_	
36-6	5558-5567	treatment	_	_	
36-7	5568-5570	to	_	_	
36-8	5571-5581	adequately	_	_	
36-9	5582-5586	heat	_	_	
36-10	5587-5594	tissues	_	_	
36-11	5595-5600	which	_	_	
36-12	5601-5605	were	_	_	
36-13	5606-5612	beyond	_	_	
36-14	5613-5616	the	_	_	
36-15	5617-5624	heating	_	_	
36-16	5625-5630	depth	_	_	
36-17	5631-5633	of	_	_	
36-18	5634-5637	the	_	_	
36-19	5638-5643	first	_	_	
36-20	5644-5653	treatment	_	_	
36-21	5653-5654	.	_	_	

#Text=Thus, repeated heating treatments are required to eventually treat sufficient tissues to obtain the therapeutic effect and benefit as is provided by the surgical method of (TURP).
37-1	5655-5659	Thus	_	_	
37-2	5659-5660	,	_	_	
37-3	5661-5669	repeated	_	_	
37-4	5670-5677	heating	_	_	
37-5	5678-5688	treatments	_	_	
37-6	5689-5692	are	_	_	
37-7	5693-5701	required	_	_	
37-8	5702-5704	to	_	_	
37-9	5705-5715	eventually	_	_	
37-10	5716-5721	treat	_	_	
37-11	5722-5732	sufficient	_	_	
37-12	5733-5740	tissues	_	_	
37-13	5741-5743	to	_	_	
37-14	5744-5750	obtain	_	_	
37-15	5751-5754	the	_	_	
37-16	5755-5766	therapeutic	_	_	
37-17	5767-5773	effect	_	_	
37-18	5774-5777	and	_	_	
37-19	5778-5785	benefit	_	_	
37-20	5786-5788	as	_	_	
37-21	5789-5791	is	_	_	
37-22	5792-5800	provided	_	_	
37-23	5801-5803	by	_	_	
37-24	5804-5807	the	_	_	
37-25	5808-5816	surgical	_	_	
37-26	5817-5823	method	_	_	
37-27	5824-5826	of	_	_	
37-28	5827-5828	(	_	_	
37-29	5828-5832	TURP	_	_	
37-30	5832-5833	)	_	_	
37-31	5833-5834	.	_	_	

#Text=By using the circulating fluid cooling within the urethra during microwave treatment, the depth of the therapeutic heating is increased because more power can be radiated without causing excessive temperatures.
38-1	5835-5837	By	_	_	
38-2	5838-5843	using	_	_	
38-3	5844-5847	the	_	_	
38-4	5848-5859	circulating	_	_	
38-5	5860-5865	fluid	_	_	
38-6	5866-5873	cooling	_	_	
38-7	5874-5880	within	_	_	
38-8	5881-5884	the	_	_	
38-9	5885-5892	urethra	_	_	
38-10	5893-5899	during	_	_	
38-11	5900-5909	microwave	_	_	
38-12	5910-5919	treatment	_	_	
38-13	5919-5920	,	_	_	
38-14	5921-5924	the	_	_	
38-15	5925-5930	depth	_	_	
38-16	5931-5933	of	_	_	
38-17	5934-5937	the	_	_	
38-18	5938-5949	therapeutic	_	_	
38-19	5950-5957	heating	_	_	
38-20	5958-5960	is	_	_	
38-21	5961-5970	increased	_	_	
38-22	5971-5978	because	_	_	
38-23	5979-5983	more	_	_	
38-24	5984-5989	power	_	_	
38-25	5990-5993	can	_	_	
38-26	5994-5996	be	_	_	
38-27	5997-6005	radiated	_	_	
38-28	6006-6013	without	_	_	
38-29	6014-6021	causing	_	_	
38-30	6022-6031	excessive	_	_	
38-31	6032-6044	temperatures	_	_	
38-32	6044-6045	.	_	_	

#Text=Excessive temperature would certainly contribute to power limiting pain, and may contribute to undesirable toxicity.
39-1	6046-6055	Excessive	_	_	
39-2	6056-6067	temperature	_	_	
39-3	6068-6073	would	_	_	
39-4	6074-6083	certainly	_	_	
39-5	6084-6094	contribute	_	_	
39-6	6095-6097	to	_	_	
39-7	6098-6103	power	_	_	
39-8	6104-6112	limiting	_	_	
39-9	6113-6117	pain	_	_	
39-10	6117-6118	,	_	_	
39-11	6119-6122	and	_	_	
39-12	6123-6126	may	_	_	
39-13	6127-6137	contribute	_	_	
39-14	6138-6140	to	_	_	
39-15	6141-6152	undesirable	_	_	
39-16	6153-6161	toxicity	_	_	
39-17	6161-6162	.	_	_	

#Text=The volume of tissue which can therefore be treated to therapeutic temperature levels in the first treatment is about 22 cm.sup.3, which is a mass of 22 grams of tissue.
40-1	6163-6166	The	_	_	
40-2	6167-6173	volume	_	_	
40-3	6174-6176	of	_	_	
40-4	6177-6183	tissue	_	_	
40-5	6184-6189	which	_	_	
40-6	6190-6193	can	_	_	
40-7	6194-6203	therefore	_	_	
40-8	6204-6206	be	_	_	
40-9	6207-6214	treated	_	_	
40-10	6215-6217	to	_	_	
40-11	6218-6229	therapeutic	_	_	
40-12	6230-6241	temperature	_	_	
40-13	6242-6248	levels	_	_	
40-14	6249-6251	in	_	_	
40-15	6252-6255	the	_	_	
40-16	6256-6261	first	_	_	
40-17	6262-6271	treatment	_	_	
40-18	6272-6274	is	_	_	
40-19	6275-6280	about	_	_	
40-20	6281-6283	22	_	_	
40-21	6284-6290	cm.sup	_	_	
40-22	6290-6292	.3	_	_	
40-23	6292-6293	,	_	_	
40-24	6294-6299	which	_	_	
40-25	6300-6302	is	_	_	
40-26	6303-6304	a	_	_	
40-27	6305-6309	mass	_	_	
40-28	6310-6312	of	_	_	
40-29	6313-6315	22	_	_	
40-30	6316-6321	grams	_	_	
40-31	6322-6324	of	_	_	
40-32	6325-6331	tissue	_	_	
40-33	6331-6332	.	_	_	

#Text=This is slightly over that normally resected by a TURP.
41-1	6333-6337	This	_	_	
41-2	6338-6340	is	_	_	
41-3	6341-6349	slightly	_	_	
41-4	6350-6354	over	_	_	
41-5	6355-6359	that	_	_	
41-6	6360-6368	normally	_	_	
41-7	6369-6377	resected	_	_	
41-8	6378-6380	by	_	_	
41-9	6381-6382	a	_	_	
41-10	6383-6387	TURP	_	_	
41-11	6387-6388	.	_	_	

#Text=Thus, the method of cooling within the prostate urethra enables the complete target tissue mass along the prostate urethra to be adequately heated in just one heating session.
42-1	6389-6393	Thus	_	_	
42-2	6393-6394	,	_	_	
42-3	6395-6398	the	_	_	
42-4	6399-6405	method	_	_	
42-5	6406-6408	of	_	_	
42-6	6409-6416	cooling	_	_	
42-7	6417-6423	within	_	_	
42-8	6424-6427	the	_	_	
42-9	6428-6436	prostate	_	_	
42-10	6437-6444	urethra	_	_	
42-11	6445-6452	enables	_	_	
42-12	6453-6456	the	_	_	
42-13	6457-6465	complete	_	_	
42-14	6466-6472	target	_	_	
42-15	6473-6479	tissue	_	_	
42-16	6480-6484	mass	_	_	
42-17	6485-6490	along	_	_	
42-18	6491-6494	the	_	_	
42-19	6495-6503	prostate	_	_	
42-20	6504-6511	urethra	_	_	
42-21	6512-6514	to	_	_	
42-22	6515-6517	be	_	_	
42-23	6518-6528	adequately	_	_	
42-24	6529-6535	heated	_	_	
42-25	6536-6538	in	_	_	
42-26	6539-6543	just	_	_	
42-27	6544-6547	one	_	_	
42-28	6548-6555	heating	_	_	
42-29	6556-6563	session	_	_	
42-30	6563-6564	.	_	_	
